The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, built its growth strategy around a highly scalable, software-driven platform that becomes more powerful as usage expands. The company’s digital infrastructure connects consumers, licensed providers, fulfillment and diagnostics into a single system, allowing each interaction to improve personalization and efficiency. Management emphasizes that scale does not simply add volume; it strengthens data feedback loops that refine treatment recommendations, improve retention and support a growing mix of multi-condition and proactive care. This platform-centric approach has supported rapid subscriber growth while maintaining operating leverage, as technology and development investments increasingly translate into broader reach and deeper engagement.
Recent launches underscore how software and data enable expansion across new categories without rebuilding the core operating model. Weight loss, alongside low testosterone, menopause and perimenopause, and upcoming whole-body lab testing, is delivered through a unified digital workflow that combines at-home testing, ongoing provider support, and data-driven personalization. The planned rollout of comprehensive lab testing and the longevity specialty further extends this model, positioning data as the entry point for proactive and preventive health management rather than episodic treatment.
At the same time, Hims & Hers is reinforcing its platform with targeted investments in AI, data pipelines and vertically integrated infrastructure. Capital raised in 2025 is earmarked to deepen these capabilities, while international expansion into Europe and Canada leverages the same software backbone. Together, these developments highlight a strategy where scalable technology and data — not physical footprint — remain the primary engines of growth.
TDOC & AMWL’s Platform-Led Scaling of Virtual Care
Teladoc Health, Inc. TDOC continues to emphasize scalability by anchoring growth in software, data integration and platform breadth. Teladoc Health positions its Prism care delivery platform as the backbone that unifies clinical workflows, real-time data and provider collaboration at scale. Recent enhancements to TDOC’s 24/7 Care expand the range of treatable conditions while leveraging integrated claims and health data to drive preventive action. Teladoc Health is further extending this model through AI-enabled Clarity monitoring, reinforcing how data-driven infrastructure supports scalable, system-wide virtual care.
American Well Corporation AMWL, popularly known as Amwell, centers its scalability strategy on the Amwell Converge platform, designed as a single, cloud-based operating system for hybrid care. Amwell enables clients to activate new use cases — ranging from virtual nursing to automated care — on the same data architecture without incremental complexity. AMWL’s continued rollout of Converge across large enterprises, including its expanded work with the U.S. Defense Health Agency, highlights how Amwell scales efficiently through standardized software, embedded analytics, and an increasingly AI-powered platform that grows alongside client demand.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 12.7% over the past year, outperforming the industry’s decline of 2.7%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.6X is lower than the industry’s average of 4.7X and its three-year median of 2.7X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpTeladoc Health, Inc. (TDOC) : Free Stock Analysis Report
American Well Corporation (AMWL) : Free Stock Analysis Report
Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
